Steven Dubovsky, MDSteven Dubovsky, MD
Psychiatry
Professor and Chair; Adjoint Professor of Psychiatry and Medicine, University of Colorado School of Medicine
University at Buffalo - Psychiatry
Erie County Medical Center
462 Grider St. Room 1182
Buffalo, NY 14215
Phone: (716) 898-5940
Fax: 716-898-4538
Email: dubovsky@buffalo.edu

View Map


OFFICE LOCATIONS

ECMC
462 Grider Street
Buffalo, NY 14215

Phone: 716-898-5940
Fax: 716-898-4538
Email: dubovsky@bufflalo.edu
View Map


DESCRIPTION OF INTERESTS

Research Interests: Calcium Metabolism in Affective Disorders; Psychopharmacology; Psychosomatic Medicine; Medical Education. Clinical specialties: mood disorders, psychosis, interactions between medical and psychiatric disorders, psychopharmacology, difficult diagnoses, complex clinical entities


SPECIALTIES

Children and Adults
Psychiatry
Molecular and Cellular Biology
Neuropharmacology
Signal Transduction


LICENSE AND CERTIFICATION

Certification, American Board of Psychiatry and Neurology, 1975


EDUCATION

1973 Residency, Psychiatry
University of Colorado Medical Center
1973 Fellowship, Psychiatry
University of Colorado
1970 Internship, Medicine
Vancouver General Hospital
1969 MD, Medicine
New York University School of Medicine
1965 AB, French Literature
New York University
Magna Cum Laude
Phi Beta Kappa


EXPERTISE

Children and Adults; Psychiatry
Research Interests: Calcium Metabolism in Affective Disorders; Psychopharmacology; Psychosomatic Medicine; Medical Education. Clinical specialties: mood disorders, psychosis, interactions between medical and psychiatric disorders, psychopharmacology, difficult diagnoses, complex clinical entities.


PUBLICATIONS

Dubovsky SL, Frobose C, Phiri P, de Greef R, Panagides J; Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.; Int J Geriatr Psychiatry; 2012 May; 27(5); 472-482
Gendel MH, Brooks E, Early SR, Gundersen DC, Dubovsky SL, Dilts SL, Shore JH; Self-prescribed and other informal care provided by physicians: scope, correlations and implications.; J Med Ethics; 2012 Feb;
Dubovsky SL, Dubovsky AN; Maintenance treatment of bipolar disorder with ziprasidone in adjunctive use with lithiuim or valproate; Clinical Medicine Insights: Therapeutics; 2012; 4; 1-8
Dubovsky SL, Leonard KE, Griswold K, Daurignac EC, Hewitt B, Fox C, Seymour D, Dubovsky AN, DeGruy F; Bipolar disorder is common in depressed primary care patients.; Postgrad Med; 2011 Sep; 123(5); 129-133
Dubovsky SL, Frobose C, Phiri P, Greef R, Panagides J; Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.; Int J Geriatr Psychiatry; 2011 Jul;
Dubovsky SL, Dubovsky AN; Ziprasidone for maintenance treatment of bipolar I disorder in adults.; Expert Opin Pharmacother; 2011 Apr; 12(5); 817-824
Dubovsky SL, Tan AR; Dextromethorphan/quinidine for pseudobulbar affect.; Current Psychiatry; 2011; 10; 60-67
Dubovsky SL, Dubovsky AN; Geriatric neuropsychopharmacology. In: Coffey E, Cummings J: Textbook of Geriatric Neuropsychiatry; ; 2011;
Dubovsky SL; Review of The Risks of Prescription Drugs Edited by Douglas W Light. Am J Psychiatry; ; 2011; 168; 1124-1125
Dubovsky SL; Review of The Risks of Prescription Drugs Edited By Douglas W. Light; American Journal Psychiatry; 2011; 168; 1124-1125
Dubovsky SL, Warren CG; Are anxiety and panic related to hypertension? in: Toth PP, Sica DA: Clinical Challenges in Hypertension; ; 2010;
Dubovsky SL, Kaye DL, Pristach CA, Del Regno P, Pessar L, Stiles K; Can academic departments maintain industry relationships while promoting physician professionalism?; Acad Med; 2010 Jan; 85(1); 68-73
Dubovsky SL, Warren C; Agomelatine, a melatonin agonist with antidepressant properties.; Expert Opin Investig Drugs; 2009 Oct; 18(10); 1533-1540
Dubovsky SL, Dubovsky AN; Psychopharmacology for neurologists.; Semin Neurol; 2009 Jul; 29(3); 200-219
Dubovsky SL; Barbiturates and related drugs. In: Sadock BJ, Sadock VA, Ruiz P: Comprehensive Textbook of Psychiatry, 9th Ed.; ; 2009;
Dubovsky SL; Calcium channel inhibitors. In:Sadock BJ, Sadock VA, Ruiz P: Comprehensive Textbook of Psychiatry 9th Ed; ; 2009;
Dubovsky SL; Drugs acting on the benzodiazepine receptor. In: Sadock BJ, Sadock VA, Ruiz P: Comprehensive Textbook of Psychiatry, 9th Ed.; ; 2009;
Dubovsky SL; Hypertension and psychiatric disorders. In Izzo JL, Sica DA, Black HR (eds): Hypertension Primer, 4th Ed.; ; 2009;
Boora K, Chiappone K, Dubovsky SL; Oxcarbazepine-induced reversible anorgasmia and ejaculatory failure: a case report.; Prim Care Companion J Clin Psychiatry; 2009 Jan; 11(4); 173-174
Dubovsky SL, Gendel MH, Dubovsky AN, Levin R, Rosse J, House R; Can admissions interviews predict performance in residency?; Acad Psychiatry; 2008 Nov; 32(6); 498-503
Dubovsky SL, Dubovsky AN; Mood disorders and the outcome of suicidal thoughts and attempts.; Crit Care Clin; 2008 Oct; 24(4); 857-874
Fava GA, Park SK, Dubovsky SL; The mental health clinic: a new model.; World Psychiatry; 2008 Oct; 7(3); 177-181
Mostert MA, Dubovsky SL; When bipolar treatment fails: What‘s your next step?; Current Psychiatry; 2008 Jan; 7; 39-46
Arciniegas DE, Dubovsky SL; Dementia due to other general medical conditions and demential due to multiple etiologies. In: Gabbard GO(ed): Treatments of Psychiatric Disorders; ; 2007;
Wolin R., Dubovsky SL, Cowan RB; Depression and neurology. In: Biller J (ed): Neurology and Internal Medicine; ; 2007;
Dubovsky SL; Psychotropic Drug Prescriber's Survival Guide: How to Practive Ethically in the Era of Big Pharma; ; 2007;
Dubovsky SL, Gendel M, Dubovsky AN, Rosse J, Levin R, House R; Do data obtained from admissions interviews and resident evaluations predict later personal and practice problems?; Acad Psychiatry; 2005 Nov; 29(5); 443-447
Dubovsky SL; Treatment of bipolar depression.; Psychiatr Clin North Am; 2005 Jun; 28(2); 349-370
Dubovsky SL, Tinyakov PG, Tkachev II; Massive graviton as a testable cold-dark-matter candidate.; Phys Rev Lett; 2005 May; 94(18); 181102-181102
Dubovsky SL; Who is teaching psychopharmacology? Who should be teaching psychopharmacology?; Acad Psychiatry; 2005 May; 29(2); 155-161
Dubovsky SL; Clinical Guide to Psychotropic Medications; ; 2005;
Dubovsky SL; Enhancing treatment adherence in multiple settings; Primary Psychiatry; 2005; 12; 31-32
Dubovsky SL; Reducing the risk of mania/hypomania associated with stimulant medications; Current Psychiatry; 2005; 4; 36-54
Dubovsky SL; Agents acting on the benzodiazepine receptor. In: Sadock BJ, Sadock VA: Comprehensive Textbook of Psychiatry VIII; ; 2004;
Dubovsky SL; Calcium channel inhibitors. In: Sadock BJ, Sadock VA: Comprehensive Textbook of Psychiatry VIII; ; 2004;
Dubovsky SL; Group therapy effective for bipolar disorder. Education-based therapy may help avert relapses.; Health News; 2003 Jun; 9(6); 4-4
Feltner, DE, Crockett JG, Dubovsky SL, Cohu, CK,, Shrivastava, RK, Targum, SD, Liu-Dumaw, M, Carter, CM, Pande, AC; A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder; J. Clin Psychopharmacology; 2003; 23(3); 240-249
Dubovsky SL, Dubovsky AN; Concise Guide to Mood Disorders; ; 2002;
Dubovsky SL, Davies R, Dubovsky AN; Mood Disorders. In: Hales RE, Yudofsky SC, Talbott JA: American Psychiatric Press Textbook of Psychiatry; ; 2002;
Maxmen JS, Ward NG, Dubovsky SL(special consultant); Psychotropic Drugs Fast Facts, Third Edition; ; 2002;
Dubovsky SL; Rapid cycling bipolar disease: new concepts and treatments.; Curr Psychiatry Rep; 2001 Dec; 3(6); 451-462
Dubovsky SL, Buzan R, Thomas M, Kassner C, Cullum CM; Nicardipine improves the antidepressant action of ECT but does not improve cognition.; J ECT; 2001 Mar; 17(1); 3-10
Dubovsky SL; Current approaches to the treatment of rapid cycling bipolar disease; Current Psychiatry Reports; 2001; 3; 451-462
Arcinegas D, Dubovsky SL; Other Forms of Dementia. In: Gabbard GO(ed): Treatment of Psychiatric Disorders (3rd Ed); ; 2001;
Dubovsky SL, Tinyakov PG, Tkachev II; Statistics of clustering of ultrahigh energy cosmic rays and the number of their sources.; Phys Rev Lett; 2000 Aug; 85(6); 1154-1157
Dubovsky SL; Are antidepressants addictive?; Health News; 2000 Feb; 6(2); 10-10
Salbenblatt MJ, Buzan RD, Dubovsky SL; Risperidone treatment for psychosis in end-stage Friedreich's ataxia.; Am J Psychiatry; 2000 Feb; 157(2); 303-303
Dubovsky SL; Duration of antidepressant treatment and risk of relapse or recurrence; Directions in Psychiatry; 2000; 20; 115-126
Dubovsky SL, Buzan R; Psychopharmacology. In: Coffee CE, Cummings JL: Textbook of Geriatric Neuropsychiatry; ; 2000;
Davies RD, Dubovsky SL, Gabbert S, Chapman M; Treatment resistance in anxiety disorders.; Bull Menninger Clin; 2000 Jan; 64(3 Sup); 22-36
Dubovsky SL, Group for Advancement of Psychiatry; Healthcare reform and postgraduate psychiatric education: Challenges and solutions.; Academic Psychiatry; 1999; 23; 1-8
Dubovsky SL; Mind, Body and Mood> In: Levinson D, Ponzetti J, Jorgensen P (eds): Encyclopedia of Human Emotions; ; 1999;
Dubovsky SL, Buzan RD; Mood Disorders. In: Hales RE, Yudofsky SC, Talbott JA: American Psychiatric Press Textbook of Psychiatry.; ; 1999;
Meis, J.L, Noll, E.L., Hevitt, S., Dubovsky SL, Filley, C.; Visuospatial instruction in Alzheimer’s disease.; J. Invest. Med; 1999; 47; 80A
Buzan RD, Dubovsky SL; Recurrence of lamotrigine-associated rash with rechallenge.; J Clin Psychiatry; 1998 Feb; 59(2); 87-87
Dubovsky SL; Cost-effective diagnosis and treatment of depression in primary care practice; Primary Care Case Reviews; 1998; 1; 31-45
Dubovsky SL; Dubovsky SL: Calcium channel antagonists as novel treatments for manic depressive disorder. In: Schatzberg AF, Nemeroff CB (eds): American Psychiatric Press Textbook of Psychopharmacology (2nd edition); ; 1998;
Giese AA, Thomas MR, Dubovsky SL, Hilty S; The impact of a history of childhood abuse on hospital outcome of affective episodes.; Psychiatr Serv; 1998 Jan; 49(1); 77-81
Buzan RD, Dubovsky SL, Firestone D, Dal Pozzo E; Use of clozapine in 10 mentally retarded adults.; J Neuropsychiatry Clin Neurosci; 1998 Jan; 10(1); 93-95
Thomas MR, Fryer GE, Rosenberg SA, Kassner C, Dubovsky SL, Shore JH; Examining the link between high-volume providers and shorter inpatient stays.; Psychiatr Serv; 1997 Nov; 48(11); 1396-1398
Thomas MR, Fryer GE, Rosenberg SA, Kassner C, Dubovsky SL, Shore JH; High volume inpatient psychiatrists have shorter lengths of stay.; Annals of Clinical Psychiatry; 1997 Sep; 9(3); 139-143
Thomas MR, Kassner CT, Fryer GE, Giese AA, Rosenberg SA, Dubovsky SL; Impact of shorter lengths of stay on status at discharge in bipolar mania.; Ann Clin Psychiatry; 1997 Sep; 9(3); 139-143
Dubovsky SL, Buzan RD; Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder.; J Clin Psychiatry; 1997 May; 58(5); 224-242
Giese AA, Thomas MR, Dubovsky SL; Dissociative symptoms in psychotic mood disorders: an example of symptom nonspecificity.; Psychiatry; 1997 Jan; 60(1); 60-66
Dubovsky SL; Mind-Body Deceptions; ; 1997;
Weintraub P., Dubovsky SL; Pharmacologic treatment of depression in adolescents.; Resident and Staff Physician; 1997; 43; 54-56
Dubovsky SL; Selected issues in the psychopharmacologic treatment of women with psychiatric disorders.; Journal of Practical Psychiatry; 1997; 3; 275-284
Thomas MR, Stoyva J, Rosenberg SA, Kassner C, Fryer GE, Giese AA, Dubovsky SL; Selection bias in an inpatient outcomes monitoring project.; Gen Hosp Psychiatry; 1997 Jan; 19(1); 56-61
Thomas MR, Rosenberg SA, Giese AA, Fryer GE, Dubovsky SL, Shore JH; Shortening length of stay without increasing recidivism on a university-affiliated inpatient unit.; Psychiatr Serv; 1996 Sep; 47(9); 996-998
Dubovsky SL, Thomas M; Tardive dyskinesia associated with fluoxetine.; Psychiatr Serv; 1996 Sep; 47(9); 991-993
Thomas MR, Dubovsky SL, Cox-Young B; Impact of external versus internal case managers on hospital utilization.; Psychiatr Serv; 1996 Jun; 47(6); 593-595
Dubovsky SL; Anxiety Disorders. In. Scully JH (ed):Psychiatry (3rd Ed.); ; 1996;
Dubovsky SL, Thomas M; Approaches to the treatment of refractory depression.; J Prac Psychiatry Behav Health; 1996; 2; 14-22
Dubovsky SL, Thomas M; Concepts and treatment strategies for double depression. In: Hales RE, Yudofsky SC (eds): Practical Clinical Strategies in Treating Depression and Anxiety in a Managed Care Environment.; ; 1996;
Filley CM, Chapman MM, Dubovsky SL; Ethical concerns in the use of palliative drug treatment for Alzheimer‘s Disease.; J Neuropsychiatry Clin Neurosci; 1996 Jan; 8(2); 202-205
Dubovsky SL; Substance-Related Disorders. In: Scully JH (ed): Psychiatry (3rd Ed.); ; 1996;
Buzan RD, Firestone D, Thomas M, Dubovsky SL; Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults.; J Clin Psychiatry; 1995 Nov; 56(11); 529-532
Dubovsky SL, Thomas M; Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction.; J Psychosom Res; 1995 May; 39(4); 429-444
Buzan RD, Dubovsky SL, Treadway JT, Thomas M; Opiate antagonists for recurrent self-injurious behavior in three mentally retarded adults.; Psychiatr Serv; 1995 May; 46(5); 511-512
Dubovsky SL; Anxiety Disorders. In: Scully JH (ed): Psychiatry (Second Edition).; ; 1995;
Dubovsky SL; Calcium channel antagonists as novel treatments for manic depressive disorder. In: Schatzberg AF, Nemeroff CB (eds): American Psychiatric Press Textbook of Psychopharmacology; ; 1995;
Dubovsky SL, Butler LD; Casebook and Study Guide. Abnormal Psychology, Third Edition; ; 1995;
Dubovsky SL; Dementia due to other general medical conditions and dementia due to multiple etiologies. In: Gabbard GO (ed): Treatment of Psychiatric Disorders, Second Edition.; ; 1995;
Dubovsky SL, Thomas M; Serotonergic mechanisms and current and future psychiatric practice.; J Clin Psychiatry; 1995 Jan; 56 Su; 38-48
Dubovsky SL; Substance-Related Disorders. In: Scully JH (ed): Psychiatry (Second Edition).; ; 1995;
Dubovsky SL, Buzan R; The role of calcium channel blockers in the treatment of psychiatric disorders.; CNS Drugs; 1995; 4; 47-57
Buzan RD, Thomas M, Dubovsky SL, Treadway J; The use of opiate antagonists for recurrent self-injurious behavior.; J Neuropsychiatry Clin Neurosci; 1995 Jan; 7(4); 437-444
Dubovsky SL; Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents.; J Clin Psychiatry; 1994 Feb; 55 Su; 34-44
Dubovsky SL; Why don‘t we hear more about the calcium antagonists? An industry-academia interaction.; Biol Psychiatry; 1994 Feb; 35(3); 149-150
Dubovsky SL; Challenges and concepts in psychotic mood disorders; Bull Menn Clinic; 1994; 58; 197-214
Dubovsky SL; Challenges in conceptualizing psychotic mood disorders.; Bull Menninger Clin; 1994 Jan; 58(2); 197-214
Dubovsky SL, Thomas M, Murphy J, Hijazi A; Characterization of the increased intracellular calcium ion concentration in peripheral cells of bipolar patients and the normalization of intracellular calcium ion concentration by lithium and carbavazepine; Eur Arch Psychiatry Clin Neurosci; 1994; 243; 229-234
Dubovsky SL; Electroconvulsive therapy. In: Kaplan H, Sadock B (eds): Comprehensive Textbook of Psychiatry. Sixth Edition, Volume 2.; ; 1994;
Dubovsky SL; Geriatric neuropsychopharmacology. In: Coffey CE, Cummings JL (eds): Textbook of Geriatric Neuropsychiatry.; ; 1994;
Dubovsky SL, Thomas M, Hijazi A, Murphy J; Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder.; Eur Arch Psychiatry Clin Neurosci; 1994 Jan; 243(5); 229-234
Dubovsky SL; Approaches to developing new anxiolytics and antidepressants.; J Clin Psychiatry; 1993 May; 54 Su; 75-83
Dubovsky SL; Calcium antagonists in manic-depressive illness.; Neuropsychobiology; 1993 Jan; 27(3); 184-192
Dubovsky SL; Diagnosis and management of psychotic depression.; Directions in Psychiatry; 1993; 13(18); 1-8
Dubovsky SL, Thomas M; Psychotic depression: advances in conceptualization and treatment.; Hosp Community Psychiatry; 1992 Dec; 43(12); 1189-1198
Dubovsky SL, Murphy J, Thomas M, Rademacher J; Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients.; Am J Psychiatry; 1992 Jan; 149(1); 118-120
Dubovsky SL, Murphy J, Christiano J, Lee C; The calcium second messenger system in bipolar disorders: data supporting new research directions.; J Neuropsychiatry Clin Neurosci; 1992 Jan; 4(1); 3-14
Dubovsky SL; Recognizing and treating depression and anxiety; Med Aspects Hum Sexuality; 1991 Oct;
Dubovsky SL; What we don‘t know about psychotic depression.; Biol Psychiatry; 1991 Sep; 30(6); 533-536
Dubovsky SL, Lee C, Christiano J, Murphy J; Elevated platelet intracellular calcium concentration in bipolar depression.; Biol Psychiatry; 1991 Mar; 29(5); 441-450
Hofmann DP, Dubovsky SL; Depression and suicide assessment.; Emerg Med Clin North Am; 1991 Feb; 9(1); 107-121
Dubovsky SL; Electroconvulsive therapy as a probe of the boundaries of neuropsychiatry.; J Neuropsychiatry Clin Neurosci; 1991 Jan; 3(4); 361-363
Dubovsky SL, Lee C, Christiano J, Murphy J; Lithium lowers platelet intracellular calcium levels in bipolar patients.; Lithium; 1991; 2; 167-174
Dubovsky SL; Psychopharmacologic treatment in neuropsychiatry. In: Hales RE, Yudofsky SC (eds): Textbook of Neuropsychiatry (Second Edition); ; 1991;
Dubovsky SL; Understanding and treating depression in anxious patients.; J Clin Psychiatry; 1990 Oct; 51 Su; 3-8
Dubovsky SL, Scully JH; Hazards of long-term psychotherapy during psychiatric residency.; Psychiatry; 1990 May; 53(2); 185-194
Dubovsky SL; Generalized anxiety disorder: new concepts and psychopharmacologic therapies.; J Clin Psychiatry; 1990 Jan; 51 Su; 3-10
Dubovsky SL, Scully J; Response to Simon; Psychiatry; 1990; 53; 198-199
Dubovsky SL, Christiano J, Daniell LC, Franks RD, Murphy J, Adler L, Baker N, Harris RA; Increased platelet intracellular calcium concentration in patients with bipolar affective disorders.; Arch Gen Psychiatry; 1989 Jul; 46(7); 632-638
Dubovsky SL; Anxiety. In: Scully, J.H. (ed): Psychiatry. Philadelphia, Harwal Publishing Co.; ; 1988;
Dubovsky SL; Concise Guide to Clinical Psychiatry; ; 1988;
Dubovsky SL, Freed C; Exercise-induced bronchospasm caused by maprotiline.; Psychosomatics; 1988 Jan; 29(1); 104-106
Dubovsky SL; Psychiatric Applications of Calcium Channel Blocking Drugs.; Tod Ther Trends; 1988; 6; 59-75
Scully JH, Dubovsky SL; Psychiatric disorders. In: Schrier, RW(ed): Medicine: Diagnosis and Treatment; ; 1988;
Dubovsky SL; Substance related disorders. In: Scully, J.H. (ed): Psychiatry. Philadelphia, Harwal Publishing Co.; ; 1988;
Dubovsky SL, Franks RD, Allen S; Verapamil: a new antimanic drug with potential interactions with lithium.; J Clin Psychiatry; 1987 Sep; 48(9); 371-372
Dubovsky SL; Severe nortriptyline intoxication due to change from a generic to a trade preparation.; J Nerv Ment Dis; 1987 Feb; 175(2); 115-117
Dubovsky SL, Katz JL, Scherger JE, Uhde TW; Anxiolytics: When? Why? Which one?; Patient Care; 1987; 21; 60-81
Dubovsky SL; Intracellular calcium in affective disorders; Dir Psychiatry; 1987; 7; 1-7
Dubovsky SL, Ringel SP; Psychopharmacologic treatment in neurological practice.; J Neurol Rehab; 1987; 2; 51-66
Dubovsky SL; Psychopharmacologic treatment in neuropsychiatry. In: Hales RE, Yudofsky S.C. (eds): Textbook of Neuropsychiatry; ; 1987;
Dubovsky SL; Unusual faces of depression: recognizing and treating complicated and atypical depressive syndromes.; Therapeutic Strategies in Depression; 1987; 1; 3-14
Dubovsky SL; Coping with entitlement in medical education.; N Engl J Med; 1986 Dec; 315(26); 1672-1674
Dubovsky SL, Franks RD, Allen S, Murphy J; Calcium antagonists in mania: a double-blind study of verapamil.; Psychiatry Res; 1986 Aug; 18(4); 309-320
Dubovsky SL; Using electroconvulsive therapy for patients with neurological disease.; Hosp Community Psychiatry; 1986 Aug; 37(8); 819-825
Dubovsky SL; Calcium antagonists: a new class of psychiatric drugs?; Psychiatry Ann; 1986; 16; 724-728
Dubovsky SL, Weissberg MP; Clinical Psychiatry in Primary Care (3rd Ed) (Also published in Spanish and Japanese); ; 1986;
Dubovsky SL; Intracellular calcium in affective disorders: Evidence in favor of deranged dynamics.; Dev Psychiatry; 1986; 7; 317-319
Metzner JL, Dubovsky SL; The role of the psychiatrist in evaluating a prison mental health system in litigation.; Bull Am Acad Psychiatry Law; 1986 Jan; 14(1); 89-95
Dubovsky SL, Gay M, Franks RD, Haddenhorst A; ECT in the presence of increased intracranial pressure and respiratory failure: case report.; J Clin Psychiatry; 1985 Nov; 46(11); 489-491
Dubovsky SL, Franks RD, Schrier D; Phenelzine-induced hypomania: effect of verapamil.; Biol Psychiatry; 1985 Sep; 20(9); 1009-1014
Dubovsky SL, Haddenhorst A, Murphy J, Liechty RD, Coyle DA; A preliminary study of the relationship between preoperative depression and weight loss following surgery for morbid obesity.; Int J Psychiatry Med; 1985 Jan; 15(2); 185-196
Dubovsky SL, Gay M, Haddenhorst A, Franks R; Electroconvulsive therapy in the presence of increased intracranial pressure and respiratory failure.; J Clin Psychiatry; 1985; 46; 489-491
Dubovsky SL, Liechty RD; Psychiatric evaluation in gastric surgery for obesity.; Psychother Psychosom; 1985 Jan; 44(3); 144-150
Dubovsky SL; Review of R. Waldinger, Psychiatry for Medical Students; Psychosomatics; 1985; 26; 258-259
Dubovsky SL; The anesthesiologist and the drug abuser; Human Aspects of Anesthesiology (In Press); 1985;
Dubovsky SL; The psychophysiology of stress, illness and health. In: Simons RC (ed): Understanding Human Behavior (3rd Ed).; ; 1985;
Dubovsky SL; Acute drug and alcohol syndromes. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making.; ; 1984;
Dubovsky SL; Acute psychiatric problems related to trauma. In: Eiseman B, Moore E, Van Way C (Eds): Care of the Injured--A Practical Guide.; ; 1984;
Dubovsky SL; Agitation. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Dubovsky SL; Chronic severe self-destructive behavior. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Dubovsky SL; Couples therapy. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making. St.; ; 1984;
Dubovsky SL; Drug intoxication. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Weston JA, Dubovsky SL; Evaluating medical school graduates of a reduced course program: a preliminary report.; J Med Educ; 1984 Jan; 59(1); 1-6
Dubovsky SL; First-line drugs used to treat depression. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Dubovsky SL; How to Involve Patients in Medical Decisions; Physician and Patient; 1984; 3; 54-61
Dubovsky SL (Ed); Insight into Depression and Suicide: A Perspective for the Primary Care Physician; ; 1984;
Dubovsky SL; Lithium carbonate. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making.; ; 1984;
Dubovsky SL; New antidepressants. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making.; ; 1984;
Dubovsky SL; Psychiatric and sexual disorders. In: Schrier RW(ed): Current Medical Therapy.; ; 1984;
Dubovsky SL, Feiger A, Eiseman B (Eds); Psychiatric Decision Making; ; 1984;
Dubovsky SL; Review of Psychiatric Management for Medical Practitioners, edited by Donald S. Kornfeld and Jerry B. Finkel; Psychosomatics; 1984; 25; 340-341
Dubovsky SL; Sadness, unhappiness, misery. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Dubovsky SL; Second-line drugs used to treat depression. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Dubovsky SL; The angry patient. In: Robertson D(ed): Principles of Family Medicine.; ; 1984;
Dubovsky SL; The suicidal patient. In: Norton LW, Eiseman, B(eds): Surgical Decision Making (2nd Ed).; ; 1984;
Dubovsky SL; The therapist-patient relationship in chronic care. In: Maloney LP, Burks J, Ringel SP(eds): The Interdisciplinary Rehabilitation of MS & Neuromuscular Disease; ; 1984;
Dubovsky SL; The threatening or frightening patient. In: Dubovsky SL, Feiger A, Eiseman B (eds): Psychiatric Decision Making; ; 1984;
Dubovsky SL, Schrier RW; The mystique of medical training.; JAMA; 1983 Dec; 250(22); 3057-3058
Dubovsky SL; Psychiatry in Saudi Arabia.; Am J Psychiatry; 1983 Nov; 140(11); 1455-1459
House R, Dubovsky SL, Penn I; Psychiatric aspects of hepatic transplantation.; Transplantation; 1983 Aug; 36(2); 146-150
Dubovsky SL, Franks RD; Intracellular calcium ions in affective disorders: a review and an hypothesis.; Biol Psychiatry; 1983 Jul; 18(7); 781-797
Scully JH, Dubovsky SL, Simons RC; Undergraduate education and recruitment into psychiatry.; Am J Psychiatry; 1983 May; 140(5); 573-576
Dubovsky SL; "Talk therapy" in primary care: Realistic parameters; Physician and Patient; 1983; 2; 35-45
Dubovsky SL; Psychiatric approach to high risk obstetrics. In: Abrams R, Wexler P(eds): Medical Problems During Pregnancy; ; 1983;
Franks RD, Dubovsky SL, Lifshitz M, Coen P, Subryan V, Walker SH; Long-term lithium carbonate therapy causes hyperparathyroidism.; Arch Gen Psychiatry; 1982 Sep; 39(9); 1074-1077
Good WV, Dubovsky SL; Pseudodementia masking substance abuse and depression.; Psychosomatics; 1982 Jun; 23(6); 652-657
Dubovsky SL, Franks RD, Lifschitz M, Coen P; Effectiveness of verapamil in the treatment of a manic patient.; Am J Psychiatry; 1982 Apr; 139(4); 502-504
Dubovsky SL, Weissberg MB; Clinical Psychiatry in Primary Care: 2nd Edition; ; 1982;
Dubovsky SL, Franks RD, Lifschitz ML, Coen P, Walker SH, Subryan V; Hypocalciuric effect of lithium: a confirmatory study.; Psychoneuroendocrinology; 1982 Jan; 7(4); 355-359
Dubovsky SL; Psychiatric Problems in Neurological Practice; ; 1982;
Dubovsky SL; Psychological Management in Neurological Practice; ; 1982;
Dubovsky SL, Dilts SL; Psychiatric Problems in Family Practice; ; 1981;
Dubovsky SL; Psychiatric Problems in Primary Practice (series of 6 monographs); ; 1981;
Dubovsky SL, Dilts SL; Psychological Management in Family Practice; ; 1981;
Dubovsky SL (Ed); Psychological Management in Medical Practice (series of 6 monographs); ; 1981;
Dubovsky SL; Psychotherapeutics in Primary Care; ; 1981;
Dubovsky SL; The psychophysiology of stress, illness and health. In: Simons RC, Pardes H(eds): Understanding Human Behavior (2nd Ed); ; 1981;
Dubovsky SL, Penn I; Psychiatric considerations in renal transplant surgery.; Psychosomatics; 1980 Jun; 21(6); 481-491
Dubovsky SL; Psychiatric considerations in transplant surgery. In: Guerra F, Aldrete JA(eds): Emotional Responses to Anesthesia and Surgery; ; 1980;
Dubovsky SL; Suicide. In: Eiseman B (Ed): Prognosis in Surgical Disease; ; 1980;
Dubovsky SL, Penn I; The stress of organ transplantation; ; 1980 Jan; 1; 20-26
Dubovsky SL, Metzner JL, Warner RB; Problems with internalization of a transplanted liver.; Am J Psychiatry; 1979 Aug; 136(8); 1090-1091
Miller PD, Dubovsky SL, McDonald KM, Katz FH, Robertson GL, Schrier RW; Central, renal and adrenal effects of lithium in man.; Am J Med; 1979 May; 66(5); 797-803
Dubovsky SL; "Experimental" self-mutilation.; Am J Psychiatry; 1978 Oct; 135(10); 1240-1241
Dubovsky SL; Averting suicide in terminally ill patients.; Psychosomatics; 1978 Feb; 19(2); 113-115
Dubovsky SL; Clinical Psychiatry in Primary Care; ; 1978;
Miller P, Dubovsky SL, McDonald KM, Arnaud C, Schrier RW; Hypocalciuric effect of lithium in man; Mineral Electrolyte Metab; 1978; 1; 3-11
Weissberg MP, Dubovsky SL; Assessment of psychiatric emergencies in medical practice.; Prim Care; 1977 Dec; 4(4); 651-660
Dubovsky SL, Getto CJ, Gross SA, Paley JA; Impact on nursing care and mortality: psychiatrists on the coronary care unit.; Psychosomatics; 1977 Aug; 18(3); 18-27
Trustman R, Dubovsky SL, Titely R; Audiotry perception during general anesthesia; Int J Clin Exp Hypn; 1977; 25; 88-151
Miller PD, Dubovsky SL, Schrier RW, McDonald KM, Arnaud C; Hypocalciuric effect of lithium in man.; Adv Exp Med Biol; 1977 Jan; 81; 157-172
Dubovsky SL, Trustman R; Absence of recall after general anesthesia: implications for theory and practice.; Anesth Analg; 1976 Sep; 55(5); 696-701
Dubovsky SL; Current concepts in the differential diagnosis and treatment of depression. In: Cozzetto FC, Brettell HR (Eds.): Topics in Family Practice; ; 1976;
Dubovsky S, Miller PD, MacDonald KM, Schrier RW; Hypocalciuric effect of Lithium (Li)in man; Clin Res; 1976; 24; 156A
Dubovsky SL, Groban SE; Congenital absence of sensation.; Psychoanal Study Child; 1975 Jan; 30; 49-73
Dubovsky SL, Plummer S, Ringer L; The suicidal and terminally ill patient; Ostomy Quart; 1975; 12; 52-54
Dubovsky SL, Groban S, Berl T, Schrier RW; Letter: Water intoxication and psychosis. In comment.; Ann Intern Med; 1974 Feb; 80(2); 281-282
Dubovsky SL, Grabon S, Berl T, Schrier RW; Syndrome of inappropriate secretion of antidiuretic hormone with exacerbated psychosis.; Ann Intern Med; 1973 Oct; 79(4); 551-554
Dubovsky SL, Shore JH (eds); Current Therapy in Psychiatry;


GRANTS

January 2012 to January 2014
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia (D1050238). Sunovion
Steven Dubovsky
$200,000
January 2011 to January 2013
A 6-month, open-label,multicenter, flexible-dose extension study to the B2061032 study to evaluate the safety, tolerability &efficacy of desvenlafaxine succinate sustained-release (dvs sr) tablets in the treatment of children & adolescent patient. Pfizer
Steven Dubovsky
$200,000
January 2011 to January 2013
A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerate
Janssen
Steven Dubovsky
$74,000
January 2011 to January 2013
A fifteen-month, prospective, randomized, active-controlled, open-label, flexible-dose study of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to treatment failure in adults with schizophrenia. Ortho McNeil Janssen
Ortho McNeil Janssen
Steven Dubovsky
$150,000
January 2011 to January 2014
A long-term, multicenter, open-label study to evaluate the safety and tolerability of flexible-dose oral aripiprazole (OPC-14597) as maintenance treatment in adolescent patients with schizophrenia or child and adolescent patients with bipolar I disorder,
Otsuka
Steven Dubovsky
$150,000
January 2011 to January 2012
A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia. Lilly
Steven Dubovsky
$645,000
January 2011 to January 2014
A long-term, Phase 3, multicenter, open-label trial to evaluate the safety and tolerability of oral OPC-34712 as maintenance treatment in adults with schizophrenia. Otsuka
Steven Dubovsky
$150,000
January 2011 to January 2015
A multicenter, open-label study to assess hospitalization rates in adult subjects with schizophrenia treated prospectively for 6 months with aripiprazole IM depot compared with 6-month retrospective treatment with oral antipsychotic in a naturalistic com
Otsuka
Steven Dubovsky
$150,000
January 2011 to January 2013
A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Co
Otskuka
Steven Dubovsky
$200,000
January 2011 to January 2012
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inade
Astra Zeneca
Steven Dubovsky
$75,000
January 2011 to January 2012
A phase 3, long-term, open-label, flexible dose, extension study evaluating the safety and tolerability of LuAA21004 (15 and 20mg) in subjects with major depressive disorder. Takeda
Steven Dubovsky
$175,000
January 2011 to January 2013
A Phase 3, multicenter, double-blind, placebo-controlled study of 3 doses of LY2140023 monohydrate in the acute treatment of patients with DSM-IV-TR schizophrenia. Lilly
Lilly
Steven Dubovsky
$174,000
January 2011 to January 2012
A Phase III, multi-center, randomized, 12 week, double-blind, parallel group, placebo-controlled study to evaluate efficacy and safety of R04917838 in patients with sup-optimally controlled symptoms of schizophrenia. Genotech
Steven Dubovsky
$150,000
January 2010 to January 2013
A long-term, multicenter, open-label study to evaluate the safety and tolerability of flexible-dose oral aripiprazole (OPC-14597) as maintenance treatment in adolescent patients with schizophrenia (31-09-267). Otsuka:
Steven Dubovsky
$150,000
January 2010 to January 2011
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit
Astra Zeneca
Steven Dubovsky
$100,000
January 2010 to January 2012
A Randomized Phase 2A, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CP-601,927 Augmentation of Antidepressant Therapy in Major Depression (A3331017). Pfizer
Steven Dubovsky
$150,000
January 2010 to January 2011
Four week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in children and adolescents with bipolar I disorder. Pfizer
Pfizer
Steven Dubovsky
$75,000
January 2010 to January 2012
International, multicenter, study of a twenty-eight week, open-label, titrated oral lixivaptan administration in patients with chronic hyponatremia: Extension to studies CK-LX3401, 3405, and 3430 (CK-LX3431). Cardiokine
Steven Dubovsky
$150,000
January 2010 to January 2012
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia (CK-LX3405). Cardiokine
Steven Dubovsky
$75,000
January 2010 to January 2013
Open-label, multicenter, rollover, long-term study of aripiprazole intramuscular depot in patients with schizophrenia (31-10-270). Otsuka:
Steven Dubovsky
$150,000
January 2010 to January 2011
Randomized phase 2A, double-blind, placebo-controlled study of the efficacy and safety of CP-601,927 augmentation of antidepressant therapy in major depression. Pfizer
Pfizer
Steven Dubovsky
$100,000
January 2009 to January 2010
Antidepressant impact of lurasidone in bipolar depression.
Sumitomo Pharma
Steven Dubovsky
$250,000
January 2009 to January 2010
Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with euvolemic hyponatremia.
Cardiokine
Steven Dubovsky
$75,000
January 2009 to January 2011
Phase 3, multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and tolerability of dimebon (PF-01913539) for up to 26-weeks in patients with mild to moderate Alzheimer's disease.
Pfizer
Steven Dubovsky
$150,000
January 2008 to December 2009
A 12-week, multicenter, open label study to evaluate the effectiveness and safety of donepezil hydrochloride (E2020) in subjects with mild to severe Alzheimer’s disease residing in an assisted living facility. Esai
Steven Dubovsky
$150,000
January 2008 to January 2010
A 52-week, multicenter, double-blind, placebo-controlled study to evaluate the safety, efficacy and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia Otsuka
Steven Dubovsky
$125,000
January 2008 to December 2008
A multicenter, double-blind, flexible-dose, 6-month trial comparing the efficacy and safety of asenapine and olanzapine in stable subjects with persistent negative symptoms of schizophrenia. Pfizer
Steven Dubovsky
$100,000
January 2008 to December 2009
Comparison of divalproex plus olanzapine or placebo in mild to moderate mania. Lilly
Steven Dubovsky
$83,920
January 2008 to December 2008
Phase III, randomized, 6-month, double blind trial in subjects with bipolar disorder to evaluate the continued safety and maintenance of effect of ziprasidone plus a mood stabilizer. Pfizer
Steven Dubovsky
$120,000
January 2008 to December 2010
Phase III, randomized, placebo-controlled clinical trial to study the safety and efficacy of 3 doses of lurasidone in acutely psychotic patients with schizophrenia. Sumitomo Pharma
Steven Dubovsky
$250,000
January 2008 to January 2012
Rapid Pediatric Psychiatry Consultation Project. Tower Foundation
Steven Dubovsky
$400,000
January 2007 to December 2008
A 52-week, randomized, double-blind, placebo-controlled, multi-center, parallel-group study of the long-term efficacy, tolerability and safety of agomelatine 25 and 50 mg in the prevention of relapse of Major Depressive Disorder (MDD) following open-labe
Steven Dubovsky
$200,000
January 2007 to January 2009
A randomized, parallel group, multiple dose six-week study to evaluate safety, tolerability and pharmacokinetics of asenapine in elderly patients. Merck
Steven Dubovsky
$150,000
January 2007 to December 2008
A randomized, parallel group, multiple dose, 6-week study to evaluate the safety, tolerability and pharmacokinetics of asenapine in elderly subjects with psychosis. Pfizer: $50,000; 2007-2008
Steven Dubovsky
$100,000
January 2007 to December 2008
A three-week double-blind, multicenter, placebo controlled study evaluating the safety and efficacy of add-on ziprasidone to lithium or divalproex in mania. Pfizer
Steven Dubovsky
$60,000
January 2006 to December 2007
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia. Pfizer:
Steven Dubovsky
$150,000
January 2006 to December 2007
A Phase 3, Randomized, 6-Month, Double Blind Trial in Subjects with Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus Mood Stabilizer (vs. Placebo Plus a Mood Stabilizer) Following a Minimum of 4 Months Res
Steven Dubovsky
$250,000
January 2006 to December 2007
A Randomized, Parallel-Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects with Psychosis. Janssen:
Steven Dubovsky
$200,000
January 2006 to December 2008
Efficacy of psychiatric consultation to pediatricians treating mental disorders. Tower Foundation:
Steven Dubovsky
$100,000
January 2006 to December 2007
Ziprasidone for adolescent mania. Pfizer
Steven Dubovsky
$210,000
January 2005 to January 2005
Bipolar Disorder in Primary Care
Marcelle Mostert; Dubovsky, S
January 2005 to December 2005
Does levetiracetam lower platelet intracellular calcium ion concentration in bipolar mood disorder? UCB Pharma
Steven Dubovsky
$50,000
January 2005 to December 2006
Extended release memantine in moderate-severe Alzheimer‘s disease. Forest
Steven Dubovsky
$200,000
January 2005 to December 2006
Open-label, flexible-dose, long-term safety and efficacy study of bifeprunox in the treatment of schizophrenia. Solvay
Steven Dubovsky
$100,000
January 2005 to December 2005
Randomized, double-blind, placebo-controlled and risperidone-referenced parallel group efficacy and safety study of two fixed doses of bifeprunox in the treatment of schizophrenia. Solvay
Steven Dubovsky
$150,000
January 2004 to December 2005
Aripiprazole in refractory depression. BMS
Steven Dubovsky
$100,000
January 2004 to December 2004
Paloperidone for schizophrenia. Johnson and Johnson.
Steven Dubovsky
$250,000
January 2004 to December 2004
Prediction of Psychiatric Diagnosis with Brain Imaging Using SPECT. Brain Matters
Steven Dubovsky
$50,000
January 2003 to December 2004
Escitalopram for geriatric depression. Forest
Steven Dubovsky
$150,000
January 2003 to December 2003
Escitalopram for pediatric depression. Forest:
Steven Dubovsky
$150,000
January 2003 to December 2004
Levatiracetam effect on intracellular calcium signaling in bipolar disorder. Pharma
Steven Dubovsky
$50,000
January 2003 to December 2004
Neuramaxane in Alzheimer‘s disease. Forest
Steven Dubovsky
$250,000
January 2003 to December 2004
Neuramaxane plus donepezil in Alzheimer‘s disease. Forest
Steven Dubovsky
$250,000
January 2002 to December 2003
Evaluation of patients with bipolar disorder. Sutherland Foundation
Steven Dubovsky
$49,000
January 2002 to December 2003
Memantine plus donepezil in Alzheimer‘s disease. Forest
Steven Dubovsky
$250,000
January 2002 to December 2003
MK-1 antagonist for major depression. Merck
Steven Dubovsky
$293,000
January 2002 to December 2004
Telemedicine consultation in primary care. Pfizer
Steven Dubovsky
$30,000
January 2001 to December 2002
Ariprazole for psychosis in demented nursing home patients. Bristol Myers Squibb
Steven Dubovsky
$150,000
January 2001 to December 2002
Galantamine in Alzheimer’s disease. Janssen
Steven Dubovsky
$100,000
January 2001 to December 2002
Galantamine in Lewy body disease. Janssen
Steven Dubovsky
$150,000
January 2001 to December 2003
Memantine in Alzheimer‘s disease. Forest
Steven Dubovsky
$200,000
January 2001 to December 2005
NIDA Clinical Trials Network (Paula Riggs, P.I.):
Steven Dubovsky
January 2001 to December 2002
Valproic acid for agitation in demented nursing home patients. Abbott Laboratories
Steven Dubovsky
$100,000
January 2000 to December 2001
5HT1D antagonist in panic disorder. Pfizer
Steven Dubovsky
$150,000
January 2000 to December 2001
CP-448 (5HT1D antagonist) in major depressive disorder. Pfizer
Steven Dubovsky
$150,000
January 2000 to December 2001
Outpatient trial of sertraline in children and adolescents with major depressive disorder. Pfizer
Steven Dubovsky
$97,000
January 1999 to December 2000
Extended study of pregabalin for social phobia. Parke-Davis
Steven Dubovsky
$279,000
January 1999 to December 2000
Fluvoxamine in social phobia. Solvay
Steven Dubovsky
$79,000
January 1999 to December 2000
Injectible olanzapine versus placebo in the treatment of acute mania. Eli Lilly
Steven Dubovsky
$160,000
January 1999 to December 2000
L-deprenyl patch for depression. Somerset
Steven Dubovsky
$109,000
January 1999 to December 2000
Olanzapine versus risperidone in the treatment of agitation and psychosis in demented patients. Lilly
Steven Dubovsky
$150,000
January 1999 to December 2000
Somatostatin analogue in Alzheimer‘s disease. Fugisawa
Steven Dubovsky
$250,000
January 1998 to December 1998
Metrifonate for Alzheimer’s disease: MINT study. Bayer Laboratories
Steven Dubovsky
$30,000
January 1998 to December 1999
Olanzapine in the Reduction of Hyperprolactinermia and associated morbidity in schizophrenic
Steven Dubovsky
$26,500
January 1998 to December 1999
Olanzapine versus risperidone and placebo in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Eli Lilly
Steven Dubovsky
$115,700
January 1998 to December 1999
Placebo Controlled Study of Two Doses of Fluoxetine in Post Traumatic Stress Disorder. Eli Lilly
Steven Dubovsky
$230,000
January 1998 to December 1999
Placebo controlled trial of paroxetine in post traumatic stress disorder. Smith Kline
Steven Dubovsky
$200,000
January 1998 to December 1999
Placebo-Controlled Study of Pregabalin and Lorazepam in Patients with Generalized Anxiety Disorder. Parke-Davis Research
Steven Dubovsky
$456,000
January 1998 to December 1999
Pregabalin for generalized anxiety disorder. Parke-Davis
Steven Dubovsky
$400,000
January 1998 to December 1999
Prevalence of hyperprolactinemia in schizophrenic patients treated with antipsychotic drugs. Eli Lilly
Steven Dubovsky
$24,000
January 1998 to December 1998
Sertraline in Post Traumatic Stress Disorder. Pfizer Laboratories
Steven Dubovsky
$298,000
January 1998 to December 1998
Sertraline in Premenstrual Syndrome. Pfizer Laboratories
Steven Dubovsky
$62,000
January 1998 to December 1999
Substance P inhibitor for major depressive disorder. Novartis
Steven Dubovsky
$250,000
January 1998 to December 1999
Substance P inhibitor for social phobia. Novartis
Steven Dubovsky
$250,000
January 1997 to December 1998
Exelon for Alzheimer’s Disease, Novartis
Steven Dubovsky
$200,000
January 1996 to December 1997
E2020 (Donepezil) in Alzheimer’s Disease, Esai/Pfizer Laboratories
Steven Dubovsky
$260,000
January 1994 to December 1995
Metrifonate in Alzheimer‘s disease, Miles Laboratories
Steven Dubovsky
$375,000
January 1994 to December 1995
Physostigmine Extended Release in Alzheimer‘s disease, Forrest
Steven Dubovsky
$320,000
January 1988 to December 1990
Nimodipine in Alzheimer‘s disease, Miles Laboratories
Steven Dubovsky
$220,000
January 1979 to December 1982
5-D18-MB0035 BHM HRA
BHM HRA
Steven Dubovsky
$492,000
January 1977 to December 1982
MH l45l7, NIMH
Steven Dubovsky, $255,000
$255,000


 | HIPAA